Although elderly
patients appear to tolerate fewer cycles of IP chemotherapy, they do not
have higher objective complication rates or impaired PFS compared to
younger patients. Age alone should not limit access to IP chemotherapy.
0
comments
:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.